NCT03379428 - Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Breast NeoplasmsMalignant Neoplasm of Breast

Interventions

DRUG

Trastuzumab

8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)

DRUG

Ibrutinib 560 mg

560 mg by mouth daily

DRUG

Ibrutinib 840 mg

840 mg by mouth daily

DRUG

Ibrutinib 420 mg

420 mg by mouth daily

Trial Locations (1)

10 sites incl TX, WA, VA, and NV, Dallas